Program
tezepelumab
Also written as “Tezepelumab”, “Experimental: Tezepelumab” and “MEDI9929”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Dermatitis, Atopic · Nasal Polyps · Rhinosinusitis, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 288 open or running | phase 4since Mar 17, 2022 | Jul 30, 2013 | Jan 13, 2027phase 3 · NCT06706817 |
| Amgen | 50 open or running | phase 2since Jan 10, 2019 | Sep 18, 2008 | none ahead |
| Qilu Pharmaceutical | 11 open or running | phase 3since Dec 11, 2025 | Dec 11, 2025 | Dec 2028phase 3 · NCT07302516 |
Also a collaborator on its studies: fortrea and parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 19 studies since Sep 18, 2008.
- Feb 18, 2021Phase 3 study in Nasal PolypsAstraZeneca · NCT04851964 · 416 enrolled · United States, Canada, China and more
- Apr 5, 2021Phase 2 study in Chronic UrticariaAmgen · NCT04833855 · 183 enrolled · United States, Canada, France and more
- Aug 23, 2021Phase 3 study in Moderate to Severe AsthmaAstraZeneca · NCT05062759 · 70 enrolled · United States
- Jan 27, 2022Phase 3 study in AsthmaAstraZeneca · NCT05274815 · 305 enrolled · United States, Argentina, Belgium and more
- Mar 17, 2022Phase 4 study in AsthmaAstraZeneca · NCT05329194 · 286 enrolled · United States
- May 26, 2022Phase 3 study in AsthmaAstraZeneca · NCT05398263 · 125 enrolled · United States, Brazil, Canada and more
- Oct 13, 2022Phase 3 study in Eosinophilic EsophagitisAstraZeneca · NCT05583227 · 368 enrolled · United States, Australia, Austria and more
- Jul 20, 2023Phase 3 study in AsthmaAstraZeneca · NCT06023589 · 231 planned · United States, Argentina, Brazil and more
- Jun 10, 2024Phase 3 study in AsthmaAstraZeneca · NCT06473779 · 310 enrolled · United States, Argentina, Belgium and more
- Nov 7, 2024Phase 3 study in RhinosinusitisAstraZeneca · NCT06706817 · 181 enrolled · United States, Bulgaria, Canada and more
- Mar 3, 20252 phase 3 studies in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT06883305, NCT06878261
- Nov 25, 2025Phase 3 study in AsthmaAstraZeneca · NCT07363642 · 400 planned · China
- Dec 11, 2025Qilu Pharmaceutical's first study: phase 3 study in AsthmaNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT07302516 · 636 planned
- Mar 24, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsAstraZeneca · NCT07520162 · 230 planned · China
Ahead
- Jan 13, 2027Primary completion: phase 3 study in RhinosinusitisAstraZeneca · NCT06706817
- Jun 25, 2027Primary completion: phase 3 study in AsthmaAstraZeneca · NCT06473779
- Feb 7, 2028Primary completion: phase 3 study in AsthmaAstraZeneca · NCT07363642
- Mar 1, 2028Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal PolypsAstraZeneca · NCT07520162
TargetBeta
“Thymic stromal lymphopoietin inhibitor; Thymic stromal lymphopoietin inhibitor”ChEMBL 37, by rule
Other programs on TSLP
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tilrekimig | Pfizer | phase 3 | 11 |
| lunsekimig | Sanofi | phase 3 | 10 |
| felcorekibart | GlaxoSmithKline | phase 3 | 9 |
| SHR-1905 | Jiangsu HengRui Medicine | phase 3 | 7 |
| TQC2731 | Sino Biopharmaceutical | phase 3 | 7 |
| WIN378rule | windward-bio | phase 2 | 2 |
| CDX-622rule | Celldex Therapeutics | phase 1 | 2 |
| HXN-1013rule | Helixon Biotechnology (Suzhou) | phase 1 | 1 |
| HY6725rule | Newsoara Biopharma | phase 1 | 1 |
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07520162Chronic Rhinosinusitis With Nasal Polyps · China | 3 | Recruiting | AstraZeneca | Mar 1, 2028 | 230 |
| NCT07302516Asthma | 3 | Not yet recruiting | Qilu Pharmaceutical | Dec 2028 | 636 |
| NCT07363642Asthma · China | 3 | Recruiting | AstraZeneca | Feb 7, 2028 | 400 |
| NCT06883305Pulmonary Disease, Chronic Obstructive · United States, Brazil, Canada and more | 3 | Recruiting | AstraZeneca | Mar 13, 2029 | 990 |
| NCT06878261Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Mar 13, 2029 | 990 |
| NCT06706817Rhinosinusitis · United States, Bulgaria, Canada and more | 3 | Active, not recruiting | AstraZeneca | Jan 13, 2027 | 181 |
| NCT06473779Asthma · United States, Argentina, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Jun 25, 2027 | 310 |
| NCT06023589Asthma · United States, Argentina, Brazil and more | 3 | Recruiting | AstraZeneca | May 31, 2028 | 231 |
| NCT05583227Eosinophilic Esophagitis · United States, Australia, Austria and more | 3 | Active, not recruiting | AstraZeneca | Jul 14, 2026 | 368 |
| NCT05398263Asthma · United States, Brazil, Canada and more | 3 | Terminated | AstraZeneca | Mar 24, 2025 | 125 |
| NCT05329194Asthma · United States | 4 | Completed | AstraZeneca | Oct 1, 2025 | 286 |
| NCT05274815Asthma · United States, Argentina, Belgium and more | 3 | Completed | AstraZeneca | Sep 9, 2024 | 305 |
| NCT05062759Moderate to Severe Asthma · United States | 3 | Completed | AstraZeneca | Mar 21, 2022 | 70 |
| NCT04833855Chronic Urticaria · United States, Canada, France and more | 2 | Completed | Amgen | Dec 20, 2022 | 183 |
| NCT04851964Nasal Polyps · United States, Canada, China and more | 3 | Completed | AstraZeneca | Sep 23, 2024 | 416 |
| NCT04673630Asthma · Hungary, South Africa, United Kingdom | 1 | Completed | AstraZeneca | Sep 27, 2022 | 18 |
| NCT04362410Healthy Subjects · China | 1 | Completed | AstraZeneca | Oct 9, 2020 | 48 |
| NCT04039113Pulmonary Disease, Chronic Obstructive · United States, Canada, Denmark and more | 2 | Completed | AstraZeneca | Nov 10, 2023 | 337 |
| NCT03989544Asthma · Germany | 1 | Completed | AstraZeneca | Dec 30, 2019 | 315 |
| NCT04048343Asthma · Japan | 3 | Completed | AstraZeneca | Mar 18, 2021 | 65 |
| NCT03968978Asthma · United States, Canada, Japan and more | 3 | Completed | AstraZeneca | Jun 5, 2020 | 216 |
| NCT03927157Asthma · China, Philippines, South Korea | 3 | Completed | AstraZeneca | May 24, 2024 | 405 |
| NCT03809663Dermatitis, Atopic · United States, Australia, Canada and more | 2 | Terminated | Amgen | May 12, 2020 | 251 |
| NCT03706079Asthma · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Oct 26, 2021 | 951 |
| NCT03688074Asthma · United States, Canada, Denmark and more | 2 | Completed | AstraZeneca | Nov 16, 2020 | 116 |
| NCT03406078Asthma · United States, Argentina, Germany and more | 3 | Completed | AstraZeneca | Sep 25, 2020 | 150 |
| NCT03347279Asthma · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Sep 8, 2020 | 1,061 |
| NCT02525094Dermatitis, Atopic · United States, Australia, Canada and more | 2 | Completed | AstraZeneca | May 9, 2016 | 113 |
| NCT02512900Asthma · Poland | 1 | Completed | AstraZeneca | May 17, 2016 | 21 |
| NCT02054130Asthma · United States, Bulgaria, Czechia and more | 2 | Completed | AstraZeneca | Dec 12, 2016 | 584 |
| NCT01913028Healthy · Japan | 1 | Completed | AstraZeneca | Jan 2014 | 64 |
| NCT01405963Asthma · Canada | 1 | Completed | Amgen | Apr 5, 2013 | 31 |
| NCT00972179Healthy Volunteers | 1 | Completed | Amgen | Jan 9, 2011 | 49 |
| NCT00757042Dermatitis, Atopic | 1 | Completed | Amgen | Jan 5, 2011 | 78 |
How it is read
Names in the registry
- “Tezepelumab”, 23 entries
- “Experimental: Tezepelumab”, 4 entries
- “MEDI9929”, 2 entries
- “tezepelumab (Arm1&Arm2)”, 1 entry
- “Tezepelumab Dose 1”, 1 entry
Conditions, from the studies’ own filings
- Asthma, 20 studies
- Pulmonary Disease, Chronic Obstructive, 3 studies
- Dermatitis, Atopic, 3 studies
- Nasal Polyps, 2 studies
- Rhinosinusitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.